ABSTRACT
Tedizolid (TR-700, DA-7157; formerly torezolid), the active moiety of the prodrug tedizolid phosphate (TR-701, DA-7218; formerly torezolid phosphate), is a member of the oxazolidinone antibiotic class (Michalska et al., 2013; Locke et al., 2014b). In June 2014, tedizolid phosphate (Sivextro) was approved in the USA and became the second commercially available oxazolidinone after linezolid (Zyvox; approved 2000). It received expedited review as a Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act. Currently, tedizolid is approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) at 200 mg orally or intravenously once daily for 6 days. It is administered as the inactive prodrug tedizolid phosphate, which is rapidly converted to the active moiety by phosphatases in vivo (Locke et al., 2014b; Vera-Cabrera et al., 2006b). Antibacterial activity is conferred by the R-enantiomer (Michalska et al., 2016). The chemical name of tedizolid phosphate is [(5R)-3-{3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl) pyridin-3-yl]phenyl}-2-oxooxazolidin-5-yl]methyl hydrogen phosphate. Its molecular formula is C17H16FN6O6P and its molecular weight is 450.32 (Merck, 2014). The structural formula is shown in Figure 76.1. Chemical structure of tedizolid phosphate. (Adapted with permission from U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database. Compound Summary for CID 11234049. Tedizolid. <uri><a href="https://www.pubchem.ncbi.nlm.nih.gov/compound/11234049" target="_blank">www.pubchem.ncbi.nlm.nih.gov/compound/11234049</a></uri>. Accessed 30 June 2016.) https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig76_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
